Vivoryon Therapeutics N.V. Stock price

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Real-time Euronext Amsterdam 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
0.54 EUR +2.08% Intraday chart for Vivoryon Therapeutics N.V. +1.31% -93.37%
Sales 2023 * - Sales 2024 * - Capitalization 14.08M 15.2M
Net income 2023 * -23M -24.83M Net income 2024 * -18M -19.43M EV / Sales 2023 * -
Net cash position 2023 * 24.1M 26.02M Net cash position 2024 * 19.55M 21.11M EV / Sales 2024 * -
P/E ratio 2023 *
-0.58 x
P/E ratio 2024 *
-0.75 x
Employees 15
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.08%
1 week+1.31%
Current month-93.65%
1 month-93.81%
3 months-93.25%
6 months-95.21%
Current year-93.37%
More quotes
1 week
0.52
Extreme 0.52
0.56
1 month
0.49
Extreme 0.49
8.60
Current year
0.49
Extreme 0.49
9.93
1 year
0.49
Extreme 0.49
19.56
3 years
0.49
Extreme 0.49
23.25
5 years
0.49
Extreme 0.49
23.25
10 years
0.49
Extreme 0.49
27.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 11-12-31
Director of Finance/CFO - -
Director/Board Member 56 18-08-30
Members of the board TitleAgeSince
Chairman 74 06-12-31
Director/Board Member 54 06-12-31
Director of Finance/CFO - -
More insiders
Date Price Change Volume
24-03-28 0.54 +2.08% 157,960
24-03-27 0.529 -2.04% 226,661
24-03-26 0.54 -1.46% 137,146
24-03-25 0.548 +0.55% 78,963
24-03-22 0.545 +2.25% 73,077

Real-time Euronext Amsterdam, March 28, 2024 at 12:35 pm EDT

More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.54 EUR
Average target price
41.57 EUR
Spread / Average Target
+7,597.53%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Vivoryon Therapeutics N.V. - Euronext Amsterdam